We have shown that a soluble receptor for vascular endothelial growth factor (sVEGFR), which adsorbs VEGF and may function as a dominant-negative receptor, suppresses tumor angiogenesis and ...

The list of growth factors involved in tumor angiogenesis has grown substantially and includes vascular endothelial growth factor (VEGF ... including an anti-VEGFR-2 (Flk-1/KDR) monoclonal ...

The combined use of an anti-VEGF drug and a Dll4 ... VEGFR-2 denotes vascular endothelial growth factor receptor 2. Another mechanism that inhibits excessive angiogenesis involves vasohibin ...

Angiogenesis is a physiological process ... bevacizumab and ziv-aflibercept as anti-vascular endothelial growth factor (VEGF) agents, whereas sorafenib, sunitinib, pazopanib, axitinib ...

Biologic drugs, like anti-angiogenesis agents ... in this category are drugs that block the binding of the growth factor known as vascular endothelial growth factor (VEGF) to cells lining the ...

The first FDA-approved anti-angiogenesis drug for cancer ... Even if a drug effectively blocks one angiogenic growth factor, such as VEGF, blood vessels may still develop via other pathways.

One class of anti-angiogenesis drugs works by blocking the action of an essential protein known as vascular endothelial growth factor, or VEGF, which normally stimulates new blood vessel growth. The ...

4 Therefore, it is important to maintain this balance between pro-angiogenic and anti-angiogenic signals ... particularly through the activation of growth factor receptors. Angiogenesis is split into ...

Angiogenesis plays a critical role ... treatments blocking the vascular endothelial growth factor (VEGF) pathway - the target of approved anti-angiogenic drugs - induce the accumulation of ...

In a randomized trial of 110 patients with metastatic renal cell carcinoma, [19] treatment with the anti-VEGF antibody bevacizumab ... also represent a critical factor in optimizing ...